先声药业：附属公司与Ipsen Pharma SAS.签订独家授权许可协议

Core Viewpoint - The company announced a licensing agreement with Ipsen Pharma SAS, granting Ipsen exclusive rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside Greater China [1] Group 1: Agreement Details - The agreement allows Ipsen to obtain global exclusive rights for SIM0613, which targets LRRC15, developed by Jiangsu Xiansheng [1] - The company is entitled to receive up to $1.06 billion in total payments, which includes an upfront payment of $45 million [1] - Additional payments will be based on research, regulatory, and commercialization milestones, along with tiered royalties on sales [1]